ClinicalTrials.gg
Enrolling by invitationNCT07906041Updated Nov 2, 2026

Tirzepatide and Organ-specific Biological Aging

A Phase 2 interventional study of Tirzepatide in Longevity, Preventive Medicine and Biological Ageing, sponsored by Atria Research and Global Health Institute (ARGHI). Enrolling by invitation at 1 site in United States. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Atria Research and Global Health Institute (ARGHI) · Phase 2, Interventional, and Other

Updated Oct 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate blood-based measures of organ-specific biological age, with a particular focus on the brain, and to investigate their relationship with established clinical indicators of health and their response to treatment with tirzepatide.

02

Conditions studied

  • Longevity
  • Preventive Medicine
  • Biological Ageing
03

In context

Lead sponsor

Atria Research and Global Health Institute (ARGHI) is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable medical status (neurological, cardiovascular, and immuno inflammatory)
  • Adults age 50-75 years
  • Eligible and waitlisted for brain health program onboarding
  • Willingness to undergo serial blood sampling, wearable monitoring, and MRI
  • Willingness to be assigned to the interventional trial or non-interventional trial
  • Willingness to accept tirzepatide treatment (interventional arm)

Exclusion criteria

Exclusion Criteria:

  • Major neurodegenerative disease (e.g., dementia)
  • Clinical and correlative imaging history of ischemic or hemorrhagic stroke
  • History of myocardial infarction (ACS) or heart failure
  • Significant inflammatory, , or infectious disease or current treatments/interventions likely to distort proteomic aging measures
  • to MRI
  • Currently taking tirzepatide
  • Pre-existing indications for tirzepatide (e.g., Type 2 diabetes, obesity, or obstructive sleep apnea)
  • less than 20.0
  • Known contraindication to tirzepatide, including a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or known serious to tirzepatide
  • Active pancreatitis or history of recurrent pancreatitis
  • Severe gastroparesis
  • renal, hepatic, glycemic, or other laboratory abnormality that could increase the risk associated with tirzepatide treatment
  • Current use of insulin or insulin secretagogues (e.g., sulfonylureas)
  • Use of another incretin-based therapy unless discontinued for at least 35 days prior to enrollment
  • History of clinically significant intolerance to tirzepatide or another incretin-based therapy
  • Any other condition, illness, or medication that, in the judgment of the clinical investigative team, would make the individual an unsuitable candidate for tirzepatide or participation in this trial
  • Contraindication to a wearable ring
  • Pregnancy or lactation
  • Prisoners
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • No intervention
    Usual care

    Participants continue routine Brain Health program care without receiving tirzepatide or placebo through the study. Participants complete study assessments at baseline, Month 3, and Month 6.

  • Experimental
    Tirzepatide

    Participants receive tirzepatide by subcutaneous injection once weekly for 6 months, starting at 2.5 mg. The dose may be increased at intervals of at least 4 weeks, based on tolerability and investigator assessment, to a maximum of 10 mg weekly. Participants continue routine Brain Health program care and complete study assessments at baseline, Month 3, and Month 6.

    Drug: Tirzepatide

Interventions

  • Tirzepatide, a dual GLP-1/GIP receptor agonist, is administered by subcutaneous injection once weekly for 6 months. The starting dose is 2.5 mg weekly, with optional dose escalation in 2.5 mg increments at intervals of at least 4 weeks, based on tolerability and investigator assessment, to a maximum of 10 mg weekly.

06

What researchers measure

Primary outcomes

  1. Change in Proteomic Brain Age Gap From Baseline to Month 6

    Change from baseline to Month 6 in proteomic brain age gap, measured in years. Brain biological age is estimated using Vero Bioscience's organ aging platform, which applies machine learning models to blood protein measurements to estimate organ-specific biological age. Brain age gap is defined as the difference between this estimated brain biological age and the participant's chronological age.

    Time frame: From baseline to Month 6

Secondary outcomes

  1. Between-Group Difference in Change in Proteomic Brain Age Gap From Baseline to Month 6

    Difference between the tirzepatide-treated and observation groups in the change in proteomic brain age gap from baseline to Month 6, measured in years.

    Time frame: From baseline to Month 6

07

Study locations

1 site
  • Atria Research and Global Health Institute
    New York, New York 10022, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Apr 2028, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2026
First posted
Oct 30, 2026
StartEst.
Oct 2026
Primary completionEst.
Apr 2028
CompletionEst.
Sep 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 30, 2026
Show all 2 updates
  1. Nov 2, 2026
    Minor edits only
    + 1 other change: responsible party
  2. Oct 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07906041
Lead sponsor
Atria Research and Global Health Institute (ARGHI)
Collaborators
Vero Bioscience, Inc.
Responsible party
Bart Demaerschalk (Principal Investigator, Atria Research and Global Health Institute (ARGHI)) — Principal investigator
First posted
Oct 30, 2026
Start date
Oct 2026 (estimated)
Primary completion
Apr 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Nov 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion